Valuation: United Therapeutics Corporation

Capitalization 16.5B 15.62B 14.48B 12.95B 23.33B 1,398B 25.83B 180B 66.6B 574B 62B 60.62B 2,474B P/E ratio 2024 *
15.1x
P/E ratio 2025 * 13.3x
Enterprise value 14.34B 13.57B 12.58B 11.25B 20.27B 1,214B 22.44B 157B 57.86B 499B 53.86B 52.67B 2,150B EV / Sales 2024 *
4.98x
EV / Sales 2025 * 4.15x
Free-Float
-
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.26%
1 week-0.22%
Current month-0.22%
1 month-9.84%
3 months+6.96%
6 months+34.43%
Current year+68.12%
More quotes
1 week
364.76
Extreme 364.76
378.27
1 month
353.65
Extreme 353.65
412.77
Current year
208.62
Extreme 208.6249
417.82
1 year
208.62
Extreme 208.6249
417.82
3 years
158.38
Extreme 158.38
417.82
5 years
75.58
Extreme 75.58
417.82
10 years
74.31
Extreme 74.31
417.82
More quotes
Director TitleAgeSince
Chief Executive Officer 69 25/06/1996
President 52 25/06/2016
Director of Finance/CFO 56 12/03/2015
Manager TitleAgeSince
Director/Board Member 76 31/12/2001
Chairman 69 25/06/1996
Director/Board Member 90 31/12/2001
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-1.26%-0.22%+52.98%+90.61%16.5B
+0.42%-0.80%+58.63%-29.66%43B
+1.35%+0.89%-5.88%-25.56%36.78B
-0.50%-3.69%+7.39%-7.93%26.11B
+3.81%+3.43%-20.18%-21.89%17.95B
+3.49%+3.20%-44.67%-84.32%17.1B
+0.84%-1.13%+9.08%-38.08%11.84B
+2.40%+2.91%+23.78%+64.07%10.87B
+0.14%-3.64%-6.19%-47.59%9.81B
-0.02%-0.02%+0.83%-23.09%9.65B
Average +1.07%+0.22%+7.58%-12.34% 19.96B
Weighted average by Cap. +1.00%+0.15%+12.82%-16.06%
See all sector performances

Financials

2024 *2025 *
Net sales 2.88B 2.73B 2.53B 2.26B 4.07B 244B 4.51B 31.46B 11.63B 100B 10.83B 10.59B 432B 3.18B 3.01B 2.79B 2.5B 4.5B 269B 4.98B 34.72B 12.84B 111B 11.95B 11.68B 477B
Net income 1.19B 1.13B 1.05B 936M 1.69B 101B 1.87B 13.03B 4.82B 41.53B 4.48B 4.38B 179B 1.29B 1.22B 1.13B 1.01B 1.82B 109B 2.02B 14.06B 5.2B 44.83B 4.84B 4.73B 193B
Net Debt -2.16B -2.05B -1.9B -1.7B -3.06B -183B -3.39B -23.63B -8.74B -75.32B -8.13B -7.95B -325B -3.29B -3.12B -2.89B -2.58B -4.66B -279B -5.15B -35.94B -13.29B -115B -12.37B -12.09B -494B
More financial data * Estimated data
Logo United Therapeutics Corporation
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Employees
1,168
More about the company
Date Price Change Volume
06/12/24 369.67 $ -1.26% 199,272
05/12/24 374.37 $ -0.01% 241,661
04/12/24 374.40 $ +1.52% 151,255
03/12/24 368.79 $ -0.36% 235,135
02/12/24 370.12 $ -0.10% 315,271

Delayed Quote Nasdaq, December 06, 2024 at 09:00 pm

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B+
surperformance-ratings-light-chart UNITED-THERAPEUTICS-CORPOMore Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
369.67USD
Average target price
382.22USD
Spread / Average Target
+3.40%
Consensus

Quarterly revenue - Rate of surprise